Related references
Note: Only part of the references are listed.
Review
Immunology
Anuraag Jena et al.
Summary: The treatment for COVID-19 often involves immune-modulating drugs, which are also used in immune mediated inflammatory diseases (IMIDs). This systematic review examines the seroconversion after SARS-CoV-2 vaccination in patients with IMIDs and the impact of different drugs on seroconversion rates. The findings suggest that patients with IMIDs have lower seroconversion rates, and certain therapies have no impact on seroconversion rates while others result in poorer responses.
AUTOIMMUNITY REVIEWS
(2022)
Article
Medicine, General & Internal
Luuk Wieske et al.
Summary: This study assessed the occurrence and risk factors for short-term adverse events (AEs) following repeated SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases (IMIDs). The study found that most AEs resolved within 7 days and hospital admissions and allergic reactions were rare.
Article
Biochemistry & Molecular Biology
Leila Mobasheri et al.
Summary: Viruses may trigger autoimmunity through mechanisms such as molecular mimicry and cytokine storm, while chronic inflammation can also contribute to autoimmune diseases. The relationship between Covid-19 and autoimmune diseases has been established.
Article
Gastroenterology & Hepatology
Neil Chanchlani et al.
Summary: Anti-TNF treatment is associated with lower seroprevalence of SARS-CoV-2 nucleocapsid antibodies and antibody reactivity compared to vedolizumab-treated patients. Higher seropositivity rates in patients with undetectable anti-TNF levels suggest a causal relationship, though other factors like combination therapy with immunomodulators may have influenced the results.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Rheumatology
Tommaso Schioppo et al.
Summary: This study aims to describe the impact of SARS-CoV-2 in SLE patients. The results indicate that SARS-CoV-2 infection can trigger autoimmune flares in a small number of SLE patients. Asymptomatic infections are more common in SLE patients with major organ involvement. This may be due to the immunosuppressive effects of medications used in SLE treatment.
Editorial Material
Medicine, General & Internal
Helene Vaillant-Roussel et al.
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE
(2022)
Article
Rheumatology
Laura Boekel et al.
Summary: This study investigated the disease severity of COVID-19 in patients with rheumatic immune-mediated inflammatory diseases (IMIDs) and the development of SARS-CoV-2 antibodies in these patients. The study found that patients with IMIDs, especially those treated with B-cell targeting therapy, were more likely to be hospitalized when infected with SARS-CoV-2. However, treatment with other drugs did not have negative effects on the development of long-lasting humoral immunity against SARS-CoV-2.
Editorial Material
Rheumatology
Rebecca H. Haberman et al.
LANCET RHEUMATOLOGY
(2022)
Article
Rheumatology
Laura Boekel et al.
Summary: This study aimed to compare the incidence and severity of SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases using immunosuppressants and controls, as well as explore the determinants of breakthrough infections, including humoral immune responses after vaccination. The study found that the incidence and severity of breakthrough infections in patients on immunosuppressants were similar to those in controls. However, caution might still be warranted for those on anti-CD20 therapy and those with traditional risk factors.
LANCET RHEUMATOLOGY
(2022)
Article
Rheumatology
Luuk Wieske et al.
Summary: Specific immunosuppressants may impair humoral responses after SARS-CoV-2 vaccination. Most patients receiving immunosuppressant therapy show similar humoral responses to controls after standard vaccination, although antibody titres may be moderately reduced. However, a third vaccination can enhance immune responses in patients with poor humoral responses.
LANCET RHEUMATOLOGY
(2022)
Article
Virology
Ulf Martin Geisen et al.
Summary: The humoral immune response declines more rapidly with TNF-alpha inhibition in patients with chronic inflammatory disease. The efficacy of current vaccines against Omicron variants, including BA.2, is limited. Alterations in immune cell populations, changes in IgG affinity, and the ability to neutralize the virus were investigated in these at-risk patients.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Rheumatology
Michael Di Iorio et al.
Summary: DMARD disruption, SARD flare, and prolonged COVID-19 symptom duration were common among COVID-19 survivors with systemic autoimmune rheumatic diseases (SARDs).
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2022)
Article
Biology
Niels J. M. Verstegen et al.
Summary: This study analyzed the immune responses to SARS-CoV-2 vaccination in MS and RA patients treated with immunosuppressants. The results showed that MS patients treated with OCR still exhibited a CD8(+) T cell response after vaccination, but humoral and B cell responses were strongly impaired. In contrast, RA patients experienced delayed antibody levels and B cell reactivation following the first vaccination. These findings have important implications for guiding vaccination strategies in patients with autoimmune diseases.
Article
Rheumatology
David Simon et al.
Summary: People with immune-mediated inflammatory diseases have a lower and less durable response to SARS-CoV-2 vaccination and are at risk of losing humoral immune protection. Adjusted vaccination schedules with earlier booster doses or more frequent re-doses, or both, could better protect these individuals.
LANCET RHEUMATOLOGY
(2022)
Article
Medicine, General & Internal
Yair Goldberg et al.
Summary: This study used data from the Israeli Ministry of Health database to compare the rate of infection with the time since immunity-confering events. The results showed that the protection against reinfection decreased over time for individuals who had previously been infected or vaccinated, but it was still higher than the protection conferred after the same time had elapsed since the second dose of vaccine among those who were previously uninfected. A single dose of vaccine after infection reinforced protection against reinfection.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Rheumatology
Claudia Sengler et al.
Summary: This study investigated the clinical manifestations, course, and outcome of SARS-CoV-2 infection among children and adolescents with rheumatic and musculoskeletal diseases. The majority of patients had a mild course of infection with good outcomes, and the infection did not significantly impact the disease activity of the underlying condition in most cases.
Article
Immunology
Juan C. Sarmiento-Monroy et al.
Summary: The study found that patients with autoimmune and immune-mediated inflammatory diseases have a lower risk of developing severe disease after contracting SARS-CoV-2, including the need for intensive care treatment and mechanical ventilation, compared to the general population.
JOURNAL OF AUTOIMMUNITY
(2021)
Article
Urology & Nephrology
Hamza Sakhi et al.
Summary: This study investigates the long-term kinetics of the antibody response to SARS-CoV-2 in dialysis patients who recovered from COVID-19, revealing that 10% of patients had no initial seroconversion and IgG antibodies decayed over time. Factors associated with decline in antibodies included older age, female sex, and nonsevere clinical presentation. About 25% of patients had negative IgG antinucleocapsid serology after 6 months, while most patients maintained antispike antibodies.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2021)
Article
Clinical Neurology
Sylvia Klineova et al.
Summary: This study found that higher neurological disability and older age independently predicted hospitalization due to COVID-19. Additionally, the results demonstrate that anti-CD20 therapies significantly blunt humoral responses postinfection, a finding that carries implications with regards to natural or vaccine-mediated immunity.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2021)
Article
Gastroenterology & Hepatology
Nicholas A. Kennedy et al.
Summary: The study found that patients with inflammatory bowel disease treated with infliximab had attenuated serological responses to SARS-CoV-2 infection. Additionally, the serological response to SARS-CoV-2 infection in the infliximab-treated group was further blunted by concomitant use of immunomodulators.
Letter
Clinical Neurology
Zoe L. E. van Kempen et al.
Article
Clinical Neurology
William L. Conte
Summary: This study suggests that MS patients treated with OCR within 6 months of a COVID-19 infection have decreased odds of developing antibodies to SARS-CoV-2 compared to other disease modifying therapies. Further research is needed to analyze spike protein antibody formation in response to SARS-CoV-2 vaccines for patients on OCR.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2021)
Article
Immunology
Maurice Steenhuis et al.
Summary: The study found that most convalescent individuals were seropositive at the initial sampling, with only one seroreverting during follow-up analysis. Antibody levels declined 2-5 months after symptom onset, with a slowing rate of decline during extended follow-up indicating long-term immunological memory.
CLINICAL & TRANSLATIONAL IMMUNOLOGY
(2021)
Review
Immunology
Deborah Cromer et al.
Summary: The duration of immunity to COVID-19 and the risk of reinfection remain unclear. Immunity is crucial for long-term control of the pandemic, but studies suggest a decline in antibody responses and an increase in documented cases of reinfection with SARS-CoV-2. Understanding memory responses and immune control dynamics is essential for designing vaccines and predicting the future trajectory of the pandemic.
NATURE REVIEWS IMMUNOLOGY
(2021)
Letter
Medicine, General & Internal
F. Javier Ibarrondo et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Immunology
Erik H. Vogelzang et al.
JOURNAL OF IMMUNOLOGY
(2020)
Article
Multidisciplinary Sciences
Ania Wajnberg et al.
Review
Clinical Neurology
Nils Erik Gilhus et al.
JOURNAL OF NEUROLOGY
(2018)
Article
Rheumatology
Nadine Zeboulon-Ktorza et al.
JOURNAL OF RHEUMATOLOGY
(2013)
